Stoke Therapeutics: Zorevunersen Has Disease-Modifying Potential In Dravet Syndrome

Stoke Therapeutics, Inc.: late-stage zorevunersen for SCN1A Dravet Syndrome with durable 3-year data, Phase 3 EMPEROR and ...
The American Journal of Managed Care

Researchers Find Genetic Variant Linked With Earlier-Onset Childhood Epilepsy

A specific genetic variant of SCN1A may be associated with earlier-onset epilepsy. SCN1A variants are most commonly associated with Dravet syndrome, the most common genetic epilepsy, which is ...
EurekAlert!

Breakthrough Dravet syndrome gene therapy in mice brings new hope to families

The SCN1A gene is too large to fit into aconventional viral delivery systems. Scientists overcame this hurdle with a pioneering "split-intein" mechanism, which is like two separate trucks, delivering ...
Business Wire

Encoded Therapeutics to Present Initial ENVISION Natural History Study Data of Children With SCN1A+ Dravet Syndrome at the American Epilepsy Society 2021 Annual Meeting

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Encoded Therapeutics today announced the upcoming presentation of initial data from the ENVISION prospective natural history study of children with SCN1A+ ...
ascopubs.org

Analysis of polymorphisms in sodium channel, voltage-gated, type I, alpha subunit (SCN1A) as predictors of clinical outcome and toxicity in advanced ovarian cancer patients ...

The relationship of polymorphism Mad1 1673 G>A on outcomes in patients with advanced ovarian cancer treated with carboplatine-paclitaxel. This is an ASCO Meeting Abstract from the 2011 ASCO Annual ...